Injecting synthetic mRNAs that encode viral proteins into mice

Vaccine developers have used recombinant rat proteins and succeeded in protecting mice against Zika viruses by injecting synthetic mRNAs that encode viral proteins into animals. The mouse cells are then constructed as part of the virus that stimulates the immune system to produce antibodies to identify future infections. When the body again exposed to the pathogen, the immune system will follow its original memory to create more protective substances to prevent pathogen damage. The study, published on February 17 in Cell, followed the February 2 issue in Nature, shows that Zika's mRNA vaccine has similar positive results in both mice and monkeys. Richner and Himansu et al. have found that the modified mRNA vaccine induces immunity to the Zika virus and minimizes the cross-immune response enhancement of the Zika virus and dengue infection.

"We measured the virus in mouse blood, brain, spleen, and female mice in the uterus, and 95% of our mice did not find viral replication in our group of vaccines." said Michael Diamond, the article's senior author and an infectious disease researcher from St. Louis Washington University School of Medicine.

Rather than using a weakened virus or viral fragment to stimulate the immune system to produce an immune response, RNA vaccine induced cells to build part of the virus, and largely this part of the virus forced cells to establish more virus model. "The Zika virus injects their RNA into the cytoplasm and then hijacks the cell's own translation mechanism to produce the Zika virus antigens," said Giuseppe Ciaramella, co-senior author of the study, who is also the chief scientific officer of the modern venture capital firm Valera and specializes in infectious disease treatment Expand. "Using our vaccine, we can lead the cells to do exactly the same."

Although RNA is directed by injecting RNA to construct a complete virus, the vaccine contains RNA to direct two Zika proteins. When the vaccine RNA enters the mouse cells, it binds to the ribosome and is translated into a protein and released. These two viral proteins are not infected with any other cells, but they are sufficient to allow the immune system to recognize the Zika virus and produce an immune response.

Because the Zika virus can enter the brain, the researchers have been hesitant to use Zika's weakened virus to produce immunity. Even with the weakened Zika virus, some scientists still focus on these attenuated Zika viruses that could still cause some damage in the brain. However, using RNA vaccines, cells can quickly take RNA before the virus reaches the brain.

Another key advantage of using RNA vaccines is its adaptability. Biologists have a lot of practical ways to change the RNA chain, making it easier to customize the vaccine. Flarebio offers high-quality recombinant proteins like recombinant ITGB5 at competitive prices.